Lily Yi Li

Lily joined Sixty Degree Capital in 2017 and leads healthcare investments in North America. She has also participated in deal sourcing and due diligence on companies in other sectors and regions. During her past two years, she has directed investments into companies and funds including Antios Therapeutics, Turnstone Biologics, Schrödinger, Northern Biologics, Engage Therapeutics, Lumira Ventures, Versant Ventures, and Inovia Capital. She currently holds an observer seat on the Antios Board of Directors. She previously worked as a pharmaceutical scientist on formulation modelling, GMP system/plant design, formulation development, and CMC. Currently, she is pursuing her Ph.D in Alzheimer’s research at the University of Toronto.

Lily is passionate about drug development and making a difference in people’s life. She is supportive of both the scientific and business aspects of new ideas and start-ups with the goal of bringing new therapies and technologies to patients.